Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Perrigo's Return To OTC Roots Restoring Investor Confidence

Executive Summary

The OTC drug, infant and adult nutritionals, Rx generic topicals and API manufacturer's share price has been up since it re-stated is historical revenues from Tysabri multiple sclerosis treatment royalties and reported interim 2017 first-quarter results. Perrigo will "fully concentrate on growing" OTC portfolio.


Related Content

Perrigo’s Outgoing CEO Advocates OTC Switches, Starting With Statins
Perrigo Makes Its Rx Generics Business Look Right At Home
Perrigo Closes Q1 Earnings Saga Trying To Keep Grip On Rx Business
Perrigo Consumer Results' Significance Grows With Tysabri In Past
Perrigo Trims Workforce, Ships Tysabri License, Stays European Course
Fluticasone Spray Competition Grows With Perrigo Launch Of West-Ward Product
OTC Private Label Anchors Perrigo Amid Branded Business Turmoil
Perrigo Navigates Earnings Storm Weathering Change At Helm


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts